Investor Presentaiton

Catalysts 22 32 Post-COVID Vaccinations expected to improve throughout CY2021 AROA Direct Sales Fully dedicated field sales team. Myriad™ expected to drive growth. TELA BIO® Momentum Clinical outcomes & cost savings driving increasing adoption Product Synergies Complementary products for every phase of healing & continuum of care Clinical Data Endoform TM, Myriad™ & Symphony™ $ Reimbursement Potential for changes in the reimbursement of cell and tissue products (Symphony) in outpatient wound centres & Pipeline Products From AROA ECM platform & new single-use dead space management platform Global Expansion Regulatory approval in 49 countries AROAT™

View entire presentation